These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31859147)

  • 21. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
    Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
    J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic sclerosis: Is the epithelium a missing piece of the pathogenic puzzle?
    Asano Y; Takahashi T; Saigusa R
    J Dermatol Sci; 2019 May; 94(2):259-265. PubMed ID: 31079997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 27. Pathophysiology of systemic sclerosis: current understanding and new insights.
    Cutolo M; Soldano S; Smith V
    Expert Rev Clin Immunol; 2019 Jul; 15(7):753-764. PubMed ID: 31046487
    [No Abstract]   [Full Text] [Related]  

  • 28. Systemic sclerosis.
    Asano Y
    J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic sclerosis: from pathogenesis to targeted therapy.
    Denton CP
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Vessels Contribute to Fibrosis in Systemic Sclerosis.
    Di Benedetto P; Ruscitti P; Liakouli V; Cipriani P; Giacomelli R
    Isr Med Assoc J; 2019 Jul; 21(7):471-474. PubMed ID: 31507123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
    Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
    Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting TLRs and the inflammasome in systemic sclerosis.
    Henderson J; Bhattacharyya S; Varga J; O'Reilly S
    Pharmacol Ther; 2018 Dec; 192():163-169. PubMed ID: 30081049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on recent randomized clinical trials in systemic sclerosis.
    Boleto G; Avouac J; Allanore Y
    Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmunity in systemic sclerosis: current concepts.
    Boin F; Rosen A
    Curr Rheumatol Rep; 2007 May; 9(2):165-72. PubMed ID: 17502048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenic roles of B lymphocytes in systemic sclerosis.
    Yoshizaki A
    Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
    Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The contemporary management of systemic sclerosis.
    Eldoma M; Pope J
    Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.